Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder
Mikhail Sergeevich Zastrozhin,1,2 Elena Anatolievna Grishina,3 Nataliya Petrovna Denisenko,3 Valentin Yurievich Skryabin,2 Dmitry Dmitrievich Markov,3 Ludmila Mikhailovna Savchenko,1 Evgeny Alekseevich Bryun,1,2 Dmitry Alekseevich Sychev4 1Department of Addictology, Russian Medical Academy of Contin...
Main Authors: | Zastrozhin MS, Grishina EA, Denisenko NP, Skryabin VY, Markov DD, Savchenko LM, Bryun EA, Sychev DA |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-06-01
|
Series: | Pharmacogenomics and Personalized Medicine |
Subjects: | |
Online Access: | https://www.dovepress.com/effects-of-cyp2d6-genetic-polymorphisms-on-the-efficacy-and-safety-of--peer-reviewed-article-PGPM |
Similar Items
-
CYP2D6 gene polymorphism and apatinib affect the metabolic profile of fluvoxamine
by: Zhize Ye, et al.
Published: (2022-09-01) -
The influence of CYP3A5 polymorphisms on haloperidol treatment in patients with alcohol addiction
by: Zastrozhin MS, et al.
Published: (2017-12-01) -
Comparing the Efficacy of Fluvoxamine and Sertraline in Treating Major Depressive Disorder (MDD)
by: Seyed-Saeid Hasani-Tabatabaei, et al.
Published: (2013-12-01) -
Haloperidol augmentation of fluvoxamine in skin picking disorder: a case report
by: Luca Maria, et al.
Published: (2012-07-01) -
A comparison of the anti-anxiety effects of oral ketamine and fluvoxamine in children with separation anxiety disorder manifesting as school refusal
by: Afsaneh Karbasi Amel, et al.
Published: (2023-01-01)